Antiphosphatidylethanolamine Antibodies and Deep Vein Thrombosis in Lupus Patients with Antiphospholipid Syndrome

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x10.1111/j.1538-7836.2006.01753.x16420554Open DOISearch in Google Scholar

2. Nayfe R, Uthman I, Aoun J, Saad Aldin E, Merashli M, Khamashta MA. Seronegative antiphospholipid syndrome. Rheumatology (Oxford). 2013 Aug;52(8):1358-67. DOI: 10.1093/rheumatology/ket12610.1093/rheumatology/ket12623502076Search in Google Scholar

3. Staub HL, Bertolaccini ML, Khamashta MA. Anti- phosphatidylethanolamine antibody, thromboembolic events and the antiphospholipid syndrome. Autoimmun Rev. 2012 Dec;12(2):230-4. DOI: 10.1016/j.autrev.2012.07.00810.1016/j.autrev.2012.07.00822796282Open DOISearch in Google Scholar

4. Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev. 2014 Sep;13(9):917-30. DOI: 10.1016/j.autrev.2014.05.00110.1016/j.autrev.2014.05.00124824074Open DOISearch in Google Scholar

5. Sestak A, O’Neil KM. Familial lupus and antiphospholipid syndrome. Lupus. 2007; 16(8): 556-63. DOI: 10.1177/0961203307078071 10.1177/096120330707807117711888Search in Google Scholar

6. Bertolaccini ML, Gomez S, Pareja JF, Theodoridou A, Sanna G, Hughes GR, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis. 2005 Nov;64(11):1639-43. DOI: 10.1136/ard.2005.03582410.1136/ard.2005.035824175525915817655Open DOISearch in Google Scholar

7. Szodoray P, Tarr T, Tumpek J, Kappelmayer J, Lakos G, Poor G, et al. Identification of rare anti-phospholipid/ protein co-factor autoantibodies in patients with systemic lupus erythematosus. Autoimmunity. 2009 Sep;42(6):497-506. DOI: 10.1080/0891693090288273110.1080/0891693090288273119626489Open DOISearch in Google Scholar

8. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug;64(8):2677-86. DOI: 10.1002/art.3447310.1002/art.34473340931122553077Search in Google Scholar

9. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630-40. DOI: 10.1002/art.178035060610.1002/art.17803506061599520Open DOISearch in Google Scholar

10. Gavris C, Anghel M, Radoi M, Gheorghita E, Duca L, Pamfil G, et al. Risk of recurrent thrombosis related to antiphospholipid antibodies, soluble CD40L and P selectin serum levels in patients with antiphospholipid syndrome secondary to systemic lupus eritematosus. RRML. 2010 Sept;3(4):23-28.Search in Google Scholar

11. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus. 1997;6(5):467-73. DOI: 10.1177/09612033970060051010.1177/0961203397006005109229367Open DOISearch in Google Scholar

12. Somers E, Magder LS, Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol. 2002 Dec;29(12):2531-6.Search in Google Scholar

13. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins’ Lupus Cohort. Lupus. 2010 Apr;19(4):419-23. DOI: 10.1177/096120330936054110.1177/096120330936054120353980Open DOISearch in Google Scholar

14. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003 Mar;101(5):1827-32. DOI: 10.1182/blood-2002-02-044110.1182/blood-2002-02-044112393574Open DOISearch in Google Scholar

15. Bertolaccini ML. Antibodies to prothrombin. Lupus. 2012 Jun;21(7):729-31. DOI: 10.1177/096120331244329910.1177/096120331244329922635215Open DOISearch in Google Scholar

16. Bertolaccini ML, Murru V, Sciascia S, Sanna G, Khamashta MA. The clinical value of testing for antibodies to phosphatidylethanolamine (aPE) in patients with systemic lupus erythematosus (SLE). Thromb Res. 2012 Dec;130(6):914-8. DOI: 10.1016/j.thromres.2012.06.00810.1016/j.thromres.2012.06.00823079292Search in Google Scholar

17. Sanmarco M, Gayet S, Alessi MC, Audrain M, de Maistre E, Gris JC, et al. Antiphosphatidylethanolamine antibodies are associated with an increased odds ratio for thrombosis. A multicenter study with the participation of the European Forum on antiphospholipid antibodies. Thromb Haemost. 2007 Jun;97(6):949-54. DOI: 10.1160/TH06-10-060410.1160/TH06-10-0604Open DOISearch in Google Scholar

18. Sanmarco M, Bardin N. The contribution of antiphosphatidylethanolamine antibodies in the diagnosis of the antiphospholipid syndrome. Lupus. 2012 Jun;21(7):727-8. DOI: 10.1177/096120331243727210.1177/096120331243727222635214Open DOISearch in Google Scholar

19. Matta BN, Uthman I, Taher AT, Khamashta MA. The current standing of diagnosis of antiphospholipid syndrome associated with systemic lupus erythematosus. Expert Rev Clin Immunol. 2013 Jul;9(7):659-68. DOI: 10.1586/1744666X.2013.81118310.1586/1744666X.2013.81118323899236Open DOISearch in Google Scholar